He believes that M&A is a necessary mechanism for incentivizing early-stage biotech innovation, and blocking these deals will negatively impact the venture capital landscape.

“So, if you don't want industry to be in this negative loop where you only work on the small diseases and you actually go and tackle the big ones, you need to allow these kinds of transactions to happen.”

He advocates for focusing antitrust efforts on specific anti-competitive tactics rather than indiscriminately blocking mergers in the pharmaceutical industry.

“If bundling is the problem, focus on bundling. The problem when you just block M&A is that you deny early investors one of the biggest ways that they can make a positive outcome.”